Suppr超能文献

沙美特罗与茶碱对比:夜间哮喘患者的睡眠及疗效结果

Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.

作者信息

Wiegand L, Mende C N, Zaidel G, Zwillich C W, Petrocella V J, Yancey S W, Rickard K A

机构信息

Department of Pulmonary/Critical Care Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA.

出版信息

Chest. 1999 Jun;115(6):1525-32. doi: 10.1378/chest.115.6.1525.

Abstract

STUDY OBJECTIVES

To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma.

DESIGN

Randomized, double-blind, double-dummy, three-period crossover.

SETTING

Outpatients at a single center. Patients spent 1 night during screening and 2 nights during each study period in a sleep laboratory for completion of sleep studies.

PATIENTS

Male and female patients who were at least 18 years old with nocturnal asthma (baseline FEV1, 50 to 90% of predicted) and who required regular bronchodilator therapy. Patients on inhaled corticosteroids, cromolyn, and nedocromil were allowed into the study if their dosing remained constant throughout the study.

INTERVENTIONS

Inhaled salmeterol (42 microg per actuation), extended-release oral theophylline (titrated to serum levels of 10 to 20 microg/mL), and placebo taken twice daily.

MEASUREMENTS AND RESULTS

Efficacy measurements included nocturnal spirometry, nocturnal polysomnography, sleep questionnaires, and daily measurements of lung function and symptoms. Salmeterol was superior to theophylline (p < or = 0.05) in maintaining nocturnal FEV1 levels and was superior to placebo (p < or = 0.05) in improving morning and evening peak expiratory flow (PEF) and in decreasing nighttime albuterol use. The use of salmeterol significantly increased the percentage of days and nights with no albuterol use and decreased daytime albuterol use compared with theophylline and placebo (p < or = 0.05). Sleep quality global scores significantly improved with salmeterol and placebo (p < 0.001) but not with theophylline. The effects on sleep architecture were similar across treatment groups.

CONCLUSIONS

Salmeterol (but not theophylline) was associated with sustained improvements in morning PEF, protection from nighttime lung function deterioration, reductions in albuterol use, and improvements in patient perceptions of sleep. No differences were seen in polysomnographic measures of sleep quality.

摘要

研究目的

比较沙美特罗与缓释茶碱对夜间哮喘患者的疗效、安全性及睡眠质量的影响。

设计

随机、双盲、双模拟、三阶段交叉试验。

地点

单一中心的门诊患者。患者在筛查期间在睡眠实验室度过1个夜晚,在每个研究阶段度过2个夜晚以完成睡眠研究。

患者

年龄至少18岁的夜间哮喘男性和女性患者(基线第一秒用力呼气容积[FEV1]为预测值的50%至90%),且需要常规支气管扩张剂治疗。吸入糖皮质激素、色甘酸钠和奈多罗米治疗的患者,若在整个研究过程中用药剂量保持不变,则可纳入研究。

干预措施

吸入沙美特罗(每次吸入42微克)、口服缓释茶碱(滴定至血清水平为10至20微克/毫升)以及每日服用两次的安慰剂。

测量与结果

疗效测量包括夜间肺量计检查、夜间多导睡眠图检查、睡眠问卷以及肺功能和症状的每日测量。在维持夜间FEV1水平方面,沙美特罗优于茶碱(p≤0.05);在改善早晚呼气峰值流速(PEF)以及减少夜间沙丁胺醇使用方面,沙美特罗优于安慰剂(p≤0.05)。与茶碱和安慰剂相比,使用沙美特罗显著增加了未使用沙丁胺醇的白天和夜晚的百分比,并减少了白天沙丁胺醇的使用量(p≤0.05)。沙美特罗和安慰剂可使睡眠质量总体评分显著改善(p<0.001),而茶碱则无此效果。各治疗组对睡眠结构的影响相似。

结论

沙美特罗(而非茶碱)与晨间PEF的持续改善、预防夜间肺功能恶化、减少沙丁胺醇使用以及患者睡眠感知的改善相关。在多导睡眠图测量的睡眠质量方面未发现差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验